<DOC>
	<DOCNO>NCT01088048</DOCNO>
	<brief_summary>This study evaluate safety clinical activity idelalisib combination anti-CD20 monoclonal antibody ( mAb ) , chemotherapeutic agent , mTOR inhibitor , protease inhibitor , antiangiogenic agent , and/or immunomodulatory agent participant relapse refractory indolent B-cell non-Hodgkin lymphoma ( NHL ) , mantle cell lymphoma ( MCL ) , chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Study Investigate Idelalisib Combination With Chemotherapeutic Agents , Immunomodulatory Agents Anti-CD20 Monoclonal Antibody ( mAb ) Subjects With Relapsed Refractory Indolent B-cell Non-Hodgkin 's Lymphoma , Mantle Cell Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age ≥ 18 Previously treat relapsed refractory disease ( refractory define respond standard regimen progress within 6 month last course standard regimen ) Disease status requirement : For CLL patient , symptomatic disease mandate treatment define International Workshop Chronic Lymphocytic Lymphoma ( IWCLL ) 2008 criterion For indolent NHL MCL patient , measurable disease CT scan define least 1 lesion measure &gt; 2 cm single dimension WHO performance status ≤ 2 For men woman childbearing potential , willing use adequate contraception ( ie , latex condom , cervical cap , diaphragm , abstinence , etc . ) entire duration study . For Cohort 7 : Women child bear potential must 2 negative pregnancy test prior start Lenalidomide . Able provide write informed consent Is good candidate receive drug administer study give disease ( idelalisib , bendamustine , rituximab , ofatumumab , fludarabine , everolimus , bortezomib , chlorambucil ) , accord clinical judgment investigator Patients atypical immunophenotype ( 11:14 ) translocation cyclin D1 over‑expression ( CLL patient ) Had radiotherapy , radioimmunotherapy , biological therapy , chemotherapy , treatment investigational product within 4weeks prior baseline disease status test Had treatment short course corticosteroid symptom relief within 1‑week prior baseline disease status test Has allogeneic hematopoietic stem cell transplant Has know active central nervous system involvement malignancy Is pregnant nursing Has active , serious infection require systemic therapy . Patients may receive prophylactic antibiotic antiviral therapy discretion investigator Has absolute neutrophil count ( ANC ) &lt; 1000/µL , unless relate underlying CLL , MCL indolent NHL , latter document &gt; 50 % infiltration bone marrow tumor cell Has platelet count &lt; 75000/µL , unless relate underlying CLL , MCL , iNHL , latter document &gt; 50 % infiltration bone marrow tumor cell Has serum creatinine ≥ 2.0 mg/dL For Cohort 7 : Has creatinine clearance &lt; 60 mL/min Has serum bilirubin ≥ 2 mg/dL ( unless due Gilbert 's syndrome ) patient iNHL CLL ; patient MCL , serum bilirubin ≥ 1.5 x upper limit normal Has serum aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ≥ 2 x upper limit normal Has ChildPugh Class B C hepatic impairment Has positive test HIV antibodies Has active hepatitis B C ( confirm RNA test ) . Patients serologic evidence prior exposure eligible . Prior treatment idelalisib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>CLL</keyword>
	<keyword>non-Hodgkin lymphoma ( NHL )</keyword>
	<keyword>mantle cell lymphoma ( MCL )</keyword>
	<keyword>phosphatidylinositol 3-kinase</keyword>
	<keyword>bendamustine</keyword>
	<keyword>CD20 mAb</keyword>
	<keyword>rituximab</keyword>
	<keyword>CAL-101</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>indolent non-Hodgkin lymphoma ( iNHL )</keyword>
	<keyword>fludarabine</keyword>
	<keyword>everolimus</keyword>
	<keyword>bortezomib</keyword>
	<keyword>chlorambucil</keyword>
	<keyword>lenalidomide</keyword>
</DOC>